Search Results - "VOUTETAKIS, A"

Refine Results
  1. 1

    HNF1A gene mutations and premature ovarian failure (POF): evidence from a clinical paradigm combining MODY 3 and POF by Xekouki, P., Konstantinidou, A., Tatsi, C., Sertedaki, A., Settas, N., Loutradis, D., Chrousos, G. P., Kanaka-Gantenbein, C., Dacou-Voutetakis, C., Voutetakis, A.

    Published in Hormones (Athens, Greece) (01-06-2024)
    “…Premature ovarian failure (POF) defines the occurrence of ovarian failure prior to the age of 40. It occurs in one out of 100 women but is very rare before age…”
    Get full text
    Journal Article
  2. 2

    Isolated GNRH deficiency: genotypic and phenotypic characteristics of the genetically heterogeneous Greek population by Stamou, M I, Varnavas, P, Kentrou, M, Adamidou, F, Voutetakis, A, Jing, J, Plummer, L, Koika, V, Georgopoulos, N A

    Published in European journal of endocrinology (01-03-2017)
    “…Isolated gonadotropin-releasing hormone (GNRH) deficiency (IGD) is a rare highly heterogeneous disorder characterized by abnormal pubertal development and/or…”
    Get full text
    Journal Article
  3. 3
  4. 4

    Protein kinase A and its role in human neoplasia: the Carney complex paradigm by Bossis, I, Voutetakis, A, Bei, T, Sandrini, F, Griffin, K J, Stratakis, C A

    Published in Endocrine-related cancer (01-06-2004)
    “…The type 1 alpha regulatory subunit (R1alpha) of cAMP-dependent protein kinase A (PKA) (PRKAR1A) is an important regulator of the serine-threonine kinase…”
    Get full text
    Journal Article
  5. 5
  6. 6

    Early growth, pubertal development, body mass index and final height of patients with congenital adrenal hyperplasia: factors influencing the outcome by Manoli, I., Kanaka-Gantenbein, Ch, Voutetakis, A., Maniati-Christidi, M., Dacou-Voutetakis, C.

    Published in Clinical endocrinology (Oxford) (01-11-2002)
    “…Summary objective The management of children with congenital adrenal hyperplasia (CAH) remains a challenge, especially with regard to growth potentials. The…”
    Get full text
    Journal Article
  7. 7

    AAV5-mediated gene transfer to the parotid glands of non-human primates by Voutetakis, A, Zheng, C, Cotrim, A P, Mineshiba, F, Afione, S, Roescher, N, Swaim, W D, Metzger, M, Eckhaus, M A, Donahue, R E, Dunbar, C E, Chiorini, J A, Baum, B J

    Published in Gene therapy (01-01-2010)
    “…Salivary glands are potentially useful target sites for multiple clinical applications of gene transfer. Previously, we have shown that serotype 2…”
    Get full text
    Journal Article
  8. 8

    Rapamycin control of transgene expression from a single AAV vector in mouse salivary glands by WANG, J, VOUTETAKIS, A, PAPA, M, RIVERA, V. M, CLACKSON, T, LODDE, B. M, MINESHIBA, F, BAUM, B. J

    Published in Gene therapy (01-01-2006)
    “…Salivary glands (SGs) appear to be a useful target site for gene therapeutics. The ability to control transgene expression is essential for clinical…”
    Get full text
    Journal Article
  9. 9

    Gender differences in serotype 2 adeno-associated virus biodistribution after administration to rodent salivary glands by Voutetakis, A, Zheng, C, Wang, J, Goldsmith, C M, Afione, S, Chiorini, J A, Wenk, M L, Vallant, M, Irwin, R D, Baum, B J

    Published in Human gene therapy (01-11-2007)
    “…Salivary glands (SGs) have proven useful targets for clinical applications of gene therapeutics. In this toxicology and biodistribution study, which conforms…”
    Get more information
    Journal Article
  10. 10

    Rapamycin control of exocrine protein levels in saliva after adenoviral vector-mediated gene transfer by WANG, J, VOUTETAKIS, A, ZHENG, C, BAUM, B. J

    Published in Gene therapy (01-04-2004)
    “…Transgene-encoded therapeutic secretory proteins can be efficiently secreted from salivary glands into saliva or the bloodstream after adenoviral (Ad)-mediated…”
    Get full text
    Journal Article
  11. 11
  12. 12

    A pleiomorphic GH pituitary adenoma from a Carney complex patient displays universal allelic loss at the protein kinase A regulatory subunit 1A (PRKARIA) locus by Bossis, I, Voutetakis, A, Matyakhina, L, Pack, S, Abu-Asab, M, Bourdeau, I, Griffin, K J, Courcoutsakis, N, Stergiopoulos, S, Batista, D, Tsokos, M, Stratakis, C A

    Published in Journal of medical genetics (01-08-2004)
    “…Carney complex (CNC) is a familial multiple endocrine neoplasia syndrome associated with GH-producing pituitary tumours and transmitted as an autosomal…”
    Get full text
    Journal Article
  13. 13

    Low serum insulin values in children with multiple lesions of granuloma annulare: a prospective study by Kakourou, T, Psychou, F, Voutetakis, A, Xaidara, A, Stefanaki, K, Dacou-Voutetakis, C

    “…ABSTRACT Background  The relationship between granuloma annularae (GA) and diabetes mellitus (DM) is controversial. Objective  To investigate the relationship…”
    Get full text
    Journal Article
  14. 14

    Pituitary size fluctuation in long-term MR studies of PROP1 deficient patients: A persistent pathophysiological mechanism? by Voutetakis, A, Sertedaki, A, Livadas, S, Xekouki, P, Bossis, I, Dacou-Voutetakis, C, Argyropoulou, M I

    Published in Journal of endocrinological investigation (01-05-2006)
    “…Inactivating PROP1 gene alterations are responsible for over 50% of familial combined pituitary hormone deficiency cases. Pituitary enlargement followed by…”
    Get full text
    Journal Article
  15. 15

    Evaluation of a rapamycin-regulated serotype 2 adeno-associated viral vector in macaque parotid glands by Zheng, C, Voutetakis, A, Metzger, M, Afione, S, Cotrim, AP, Eckhaus, MA, Rivera, VM, Clackson, T, Chiorini, JA, Donahue, RE, Dunbar, CE, Baum, BJ

    Published in Oral diseases (01-04-2010)
    “…Oral Diseases (2010) 16, 269–277 Objectives:  Salivary glands are useful target organs for local and systemic gene therapeutics. For such applications, the…”
    Get full text
    Journal Article
  16. 16

    674. Administration of rAAV2 and rAAV5 to the Parotid Gland of Non-Human Primates by Voutetakis, A., Zheng, C., Chiorini, J.A., Schmidt, M., Afione, S., Metzger, M., Dunbar, C., Donahue, R.E., Baum, B.J.

    Published in Molecular therapy (01-05-2006)
    “…Previous studies from our laboratory showed that therapeutic levels of transgene expression were obtained from mouse submandibular glands after retro-ductal…”
    Get full text
    Journal Article
  17. 17

    Toxicity and biodistribution of a first-generation recombinant adenoviral vector, in the presence of hydroxychloroquine, following retroductal delivery to a single rat submandibular gland by Zheng, C, Voutetakis, A, Kok, MR, Goldsmith, CM, Smith, GBJ, Elmore, S, Nyska, A, Vallant, M, Irwin, RD, Baum, BJ

    Published in Oral diseases (01-03-2006)
    “…Objective:  We examined the toxicity and biodistribution associated with a single administration of a first‐generation, serotype 5, adenoviral vector encoding…”
    Get full text
    Journal Article
  18. 18
  19. 19

    Insufficient adrenarche in patients with combined pituitary hormone deficiency caused by a PROP-1 gene defect by Voutetakis, A, Livadas, S, Sertedaki, A, Maniati-Christidi, M, Dacou-Voutetakis, C

    “…Adrenarche was evaluated in five patients, aged 17.4 +/- 3 years, with combined pituitary hormone deficiency (CPHD), caused by a PROP-1 gene defect…”
    Get more information
    Journal Article
  20. 20

    Human Growth Hormone and Gonadotropin Releasing Hormone Analog Combination Therapy Increases Predicted Height in Short Normal Girls by Maniati-Christidi, M., Livadas, S., Voutetakis, A., Tolis, G., Dacou-Voutetakis, C.

    Published in Clinical pediatrics (01-01-2003)
    “…The “short normal” child constitutes a real challenge for the pediatric endocrinologist. In a subgroup of short normal children, puberty starts at a normal age…”
    Get full text
    Journal Article